- Home
- CVKD vs SABS Comparison
CVKD vs SABS Comparison
Compare CVKD & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- SABS
- Stock Information
- Founded
- CVKD 2022
- SABS 2014
- Country
- CVKD United States
- SABS United States
- Employees
- CVKD N/A
- SABS N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- SABS Health Care
- Exchange
- CVKD Nasdaq
- SABS Nasdaq
- Market Cap
- CVKD 26.3M
- SABS 23.9M
- IPO Year
- CVKD 2023
- SABS N/A
- Fundamental
- Price
- CVKD $14.01
- SABS $3.04
- Analyst Decision
- CVKD Strong Buy
- SABS Strong Buy
- Analyst Count
- CVKD 2
- SABS 5
- Target Price
- CVKD $46.00
- SABS $12.40
- AVG Volume (30 Days)
- CVKD 70.3K
- SABS 83.2K
- Earning Date
- CVKD 11-07-2024
- SABS 11-06-2024
- Dividend Yield
- CVKD N/A
- SABS N/A
- EPS Growth
- CVKD N/A
- SABS N/A
- EPS
- CVKD N/A
- SABS N/A
- Revenue
- CVKD N/A
- SABS $1,512,723.00
- Revenue This Year
- CVKD N/A
- SABS N/A
- Revenue Next Year
- CVKD N/A
- SABS N/A
- P/E Ratio
- CVKD N/A
- SABS N/A
- Revenue Growth
- CVKD N/A
- SABS N/A
- 52 Week Low
- CVKD $5.40
- SABS $2.16
- 52 Week High
- CVKD $32.55
- SABS $9.72
- Technical
- Relative Strength Index (RSI)
- CVKD 43.74
- SABS 47.24
- Support Level
- CVKD $15.52
- SABS $3.17
- Resistance Level
- CVKD $19.97
- SABS $3.74
- Average True Range (ATR)
- CVKD 1.80
- SABS 0.45
- MACD
- CVKD -0.44
- SABS -0.08
- Stochastic Oscillator
- CVKD 0.17
- SABS 6.34
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.